Ciclesonide, a hypotonic intranasal corticosteroid

Allergy and Asthma Proceedings

Volumn 31, Issue SUPPL. 1, 2010, Pages

  Neffen, Hugo ^a   Wingertzahn, Mark A ^b  

^a Respiratory Medicine Unit   (Argentina)

^b Nycomed GmbH   (United States)

Author keywords

Allergic rhinitis; Efficacy; Hypertonic; Intranasal corticosteroids; Nasal allergy medications; Quality of life; Safety

Indexed keywords

CICLESONIDE; CORTICOSTEROID; HYDROCORTISONE; NOSE SPRAY; PLACEBO; ANTIALLERGIC AGENT; PREGNANE DERIVATIVE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC RHINITIS; ARTICLE; BODY TEMPERATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG SAFETY; EPISTAXIS; FEVER; HEADACHE; HUMAN; INFLUENZA; MONOTHERAPY; NOSE ALLERGY; OTALGIA; OTITIS MEDIA; QUALITY OF LIFE; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SORE THROAT; STREPTOCOCCAL PHARYNGITIS; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; ADULT; CHEMISTRY; CHILD; CLINICAL TRIAL (TOPIC); INTRANASAL DRUG ADMINISTRATION; PRESCHOOL CHILD; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANTI-ALLERGIC AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; HUMANS; PREGNENEDIONES; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 77955911484     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2010.31.3348     Document Type: Article

References (38)

1. Skoner DP. Allergic rhinitis: Definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 108:S2-S8, 2001.
2. Lundbäck B. Epidemiology of rhinitis and asthma. Clin Exp Allergy Suppl 2:3-10, 1998.
3. Arshad SH. Indoor allergen exposure in the development of allergy and asthma. Curr Allergy Asthma Rep 3:115-120, 2003.
4. Nathan RA, Meltzer EO, Derebery J, et al. The prevalence of nasal symptoms attributed to allergies in the United States: Findings from the burden of rhinitis in an America survey. Allergy Asthma Proc 29:600-608, 2008.
5. Weiner JM, Abramson MJ, and Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: Systematic review of randomized controlled trials. BMJ 317:1624-1629, 1998.
6. Wallace DV, Dykewicz MS, Bernstein DI, et al., and Joint Task Force on Practice; American Academy of Allergy; Asthma & Immunology; American College of Allergy; Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122:S1-S84, 2008.
7. Ratner PH, Stoloff S, Meltzer EO, and Hadley JA. Intranasal corticosteroids in the treatment of allergic rhinitis. Allergy Asthma Proc 28(suppl 1):S25-S32, 2007.
8. Rohatagi S, Luo Y, Shen L, et al. Protein binding and it potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther 12:201-209, 2005.
9. Rohatagi S, Krishnaswami S, Pfister M, and Sahasranaman S. Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release model. Am J Ther 12:385-397, 2005.
10. Dietzel K, Engelstatter R, and Keller A. Ciclesonide: An on-siteactivated- steroid. In New Drugs for Asthma, Allergy and COPD. Prog Respir Res 31:91-93, 2001.
11. Boobis AR. Comparative physicochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonide. Respir Med 92(suppl B):2-6, 1998.
12. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide. J Clin Pharmacol 47:782-789, 2007.
13. Valotis A, Neukam K, Elert O, and Högger P. Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate. J Pharm Sci 93:1337-1350, 2004.
14. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 91(suppl A):22-28, 1997.
15. Sato H, Nave R, Nonaka T, et al. In vitro metabolism of ciclesonide in human nasal epithelial cells. Biopharm Drug Dispos 28:43-50, 2007.
16. Sato H, Nave R, Nonaka T, et al. Uptake and metabolism of ciclesonide and retention of desisobutyryl-ciclesonide for up to 24 hours in rabbit nasal mucosa. BMC Pharmacol 7:7, 2007.
17. Nave R, Wingertzahn MA, Brookman S, et al. Safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis. J Clin Pharmacol 46:461-467, 2006.
18. Kim K, Weiswasser M, Nave R, et al. Safety of once-daily ciclesonide nasal spray in children with perennial allergic rhinitis. Pediatr Asthma Allergy Immunol 20:229-242, 2007.
19. Berger WE, Nayak A, Lanier BQ, et al. Efficacy and safety of once-daily ciclesonide nasal spray in children with allergic rhinitis. Pediatr Asthma Allergy Immunol 21:73-82, 2008.
20. Nave R. Clinical pharmacokinetic and pharmacodynamic profile of inhaled ciclesonide. Clin Pharmacokinet 48:243-252, 2009.
21. Nave R, Drollmann A, Steinijans VW, et al. Lack of pharmacokinetic drug-drug interaction between ciclesonide and erythromycin. Int J Clin Pharmacol Ther 43:264-270, 2005.
22. Bernstein IL. Is the use of benzalkonium chloride as a preservative for nasal formulations a safety concern? A cautionary note based on compromised mucociliary transport. J Allergy Clin Immunol 105:39-44, 2000.
23. Bachert C, and El-Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 89:292-297, 2002.
24. Wingertzahn MA, Derebery JM, and Nelson HS. Optimization of intranasal corticosteroid formulations for the treatment of allergic rhinitis. Allergy Asthma Proc 28:S18-S24, 2007.
25. Ratner PH, Wingertzahn MA, van Bavel JH, et al. Effectiveness of ciclesonide nasal spray in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 97:657-663, 2006.
26. Ratner PH, Wingertzahn MA, van Bavel JH, et al. Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 118:1142-1148, 2006.
27. Meltzer EO, Kunjibettu S, Hall N, et al. Efficacy and safety of ciclesonide, 200 microg once daily, for the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol 98:175-181, 2007. (Pubitemid 46214225)
28. Chervinsky P, Kunjibettu S, Miller DL, et al. Long-term safety and efficacy of intranasal ciclesonide in adult and adolescent patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol 99:69-76, 2007.
29. Patel P, Patel D, Kunjibettu S, et al. Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis. Ear Nose Throat J 87:340-353, 2008.
30. Couroux P, Kunjibettu S, Hall N, and Wingertzahn MA. Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 102:62-68, 2009.
31. Katial RK, Salapatek AM, and Patel P. Establishing the onset of action of intranasal corticosteroids: Is there an ideal study design? Allergy Asthma Proc 30:595-604, 2009.
32. Ratner P, Darken P, Wingertzahn M, and Shah T. Ciclesonide and beclomethasone dipropionate coadministration: Effect on cortisol in perennial allergic rhinitis. J Asthma 44:629-633, 2007.
33. Kim K, Quesada J, Szmaydy-Rikken N, et al. Intranasal ciclesonide coadministration with inhaled fluticasone propionate- salmeterol does not suppress cortisol in allergic rhinitis patients. J Asthma 44:515-520, 2007.
34. Kim K, Weiswasser M, Nave R, et al. Safety of once-daily ciclesonide nasal spray in children with perennial allergic rhinitis. Pediatr Asthma Allergy Immunol 20:229-242, 2007.
35. Broide DH. The pathphysiology of allergic rhinitis. Allergy Asthma Proc 28:398-403, 2007.
36. Benninger MS, and Benninger RM. The impact of allergic rhinitis on sexual activity, sleep, and fatigue. Allergy Asthma Proc 30:358-365, 2009.
37. Meltzer EO, Nathan R, Derebery J, et al. Sleep, quality of life, and productivity impact of nasal symptoms in the United States: Findings from the Burden of Rhinitis in America survey. Allergy Asthma Proc 30:244-254, 2009.
38. Blaiss MS. Safety considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Allergy Asthma Proc 28:145-152, 2007.